Skip to content

PSX Pharmaceuticals

LIVEN Liven Pharma Limited

Latest results: FY2026 · Jun 2026

FY2026 revenue Rs 105.8 mn (-16.9%), loss Rs 31.1 mn.

Last close · 13 Nov 2026

Rs 39.19 ▲ 3.56 (+9.99%)

▼ 19.3% 1 year

15 Oct 22 Oct 28 Oct 3 Nov 11 Nov Jun Jul Aug Sep Oct Dec Feb May Jul Oct 2022 2023 2024 2025 2026
27.8252-week range63.48
Market cap
Rs 4.4 bn
P/E
—
FY2026
P/B
4.50×
FY2026
Sector 3.11× · higher
Dividend yield
0.0%
FY2026
ROE
-3.8%
FY2026
Sector 21.7% · lower
EPS
Rs -0.28
FY2026
Book value / share
Rs 8.72
FY2026

Fundamentals

LIVEN at a glance

Revenue · FY2026

Rs 105.8 mn

▼ 16.9% year on year

Profit attributable to shareholders · FY2026

-Rs 31.1 mn

EPS – basic (Rs) · FY2026

Rs -0.28

Dividend per share (Rs) · FY2026

Rs 0.00

Net margin · FY2026

-29.4%

+429.8 pts year on year

Debt to equity · FY2026

3.4%

-2.1 pts year on year

Price performance

LIVEN returns

Close Rs 39.19
13 Nov 2026

Period Return Rs
MTD +28.1% +21.2 pts vs KSE +8.60
3M +11.9% +13.1 pts vs KSE +4.16
6M +4.8% −1.4 pts vs KSE +1.80
YTD −24.6% −26.8 pts vs KSE −12.78
FYTD −3.8% −2.4 pts vs KSE −1.53
1Y −19.3% −30.0 pts vs KSE −9.36
Long term
3Y +176.2% +40.3% a year −38.5 pts vs KSE +25.00
5Y +73.0% +11.6% a year −215.9 pts vs KSE +16.53

Price return from the last close before each period; the fiscal year ends 30 June. Dividends are not included.

Liven Pharma Limited in brief

Liven Pharma Limited (LIVEN) reported revenue of Rs 105.8 mn for FY2026 (Jul 2025 – Jun 2026), down 16.9% from FY2025.

It made a loss of Rs 31.1 mn attributable to shareholders (EPS Rs -0.28), a net margin of -29.4%.

No cash dividend was declared for FY2026.

The balance sheet showed net cash of Rs 148.1 mn.

Return on equity was -3.8%.

At Rs 39.19 (close on 13 Nov 2026) the shares trade at 4.50× book value.

Scorecard vs Pharmaceuticals

14 companies
Growth
No figure
—
Profitability
Weak
-29.4%
Financial health
Average
3.4%
Valuation
Loss-making
—
Dividends
Below average
0.0%

Ratings place the company in its sector: growth (3-year revenue growth), profitability (net margin; return on equity for banks, insurers and finance companies), financial health (debt to equity, industrial companies), valuation (P/E at today's price) and dividends (yield at today's price). Five dots = top fifth. Rated within the sector when at least four companies report the figure, otherwise against all PSX companies of the same type (marked vs PSX). Information, not investment advice.

Corporate

LIVEN announcements & payouts

All LIVEN announcements →
2 Nov 2026 · 15:45
Result · First quarter to 30 Sep 2026
Profit after tax
Rs (7.4) mn
EPS
Rs (0.07)
EPS a year earlier
Rs (0.32)
5 Oct 2026 · 15:20
Result · Full year to 30 Jun 2026 AGM 26 Oct
Profit after tax
Rs (31.1) mn
EPS
Rs (0.28)
EPS a year earlier
Rs (8.37)

Book closure 19 Oct – 26 Oct 2026

30 Apr 2026 · 10:11
Result · Nine months to 31 Mar 2026
Profit after tax
Rs (5.9) mn
EPS
Rs (0.06)
4 Mar 2026 · 12:22
Result · Half year to 31 Dec 2025
Profit after tax
Rs (1.9) mn
EPS
Rs (0.02) -100.8%
EPS a year earlier
Rs 2.46

Financial highlights

LIVEN financial results

LIVEN annual financial highlights (Rs mn)
Rs mn FY2026 Jul 2025 – Jun 2026 FY2025 * Jul 2024 – Jun 2025 FY2024 * Jul 2023 – Jun 2024 FY2023 Jul 2022 – Jun 2023 FY2022 Jul 2021 – Jun 2022 FY2021 * Jul 2020 – Jun 2021 FY2020 * Jul 2019 – Jun 2020 FY2019 Jul 2018 – Jun 2019 FY2018 Jul 2017 – Jun 2018 FY2017 Jul 2016 – Jun 2017
Revenue 105.8 127.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
Gross profit 26.6 18.0 0.0 0.0 0.0 (16.1) (17.8) (16.7) (1.9) (22.4)
Operating profit (62.4) (489.8) (13.8) (15.2) (17.5) (18.2) (20.0) (18.7) (4.6) (26.2)
Profit after tax (31.1) (584.5) (11.2) (12.3) (14.3) (14.6) (16.9) (15.2) (56.5) (37.6)
Profit attributable to shareholders (31.1) (584.5) (11.2) (12.3) (14.3) (14.6) (16.9) (15.2) (56.5) (37.6)
EPS – basic (Rs) Rs (0.28) (7.11) (0.78) (0.86) (1.00) (1.03) (1.19) (1.07) (3.96) (2.64)
Dividend per share (Rs) Rs 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total assets 1,216.0 822.9 119.7 131.5 144.6 159.6 174.4 192.3 176.8 212.9
Total equity 985.5 633.9 (133.8) (122.6) (110.3) (96.0) (77.7) (60.8) (62.3) 16.2
Total debt 33.4 34.7 238.5 237.6 235.4 233.1 226.3 224.4 222.6 165.8
Net cash from operating activities 9.0 (1.7) (0.9) (2.3) (2.3) (6.8) (1.9) (1.8) (4.8) (5.1)
Capital expenditure (29.7) (32.8) — — — — — — — —
Free cash flow (operating cash flow − capex) (20.7) (34.6) — — — — — — — —
LIVEN quarterly financial highlights (Rs mn)
Rs mn TTM to Jun 2026 Q4 FY2026 Apr – Jun 2026 Q3 FY2026 Jan – Mar 2026 Q2 FY2026 Oct – Dec 2025 Q1 FY2026 Jul – Sep 2025 Q4 FY2025 Apr – Jun 2025 Q3 FY2025 Jan – Mar 2025 Q2 FY2025 Oct – Dec 2024 Q1 FY2025 Jul – Sep 2024
Revenue 105.8 13.2 29.2 54.6 8.8 6.5 14.8 17.1 88.9
Gross profit 26.6 (3.7) 8.4 18.0 3.9 (20.1) 3.7 9.5 24.8
Operating profit (62.4) (36.7) (4.9) 10.3 (31.1) (612.5) (7.3) (9.5) 134.5
Profit after tax (31.1) (25.2) (4.0) 28.2 (30.2) (695.3) (9.6) (9.5) 147.6
Profit attributable to shareholders (31.1) (25.2) (4.0) 28.2 (30.2) (695.3) (9.6) (9.5) 147.6
EPS – basic (Rs) Rs (0.22) (0.17) (0.03) 0.25 (0.27) (9.14) (0.08) (0.08) 1.35
Dividend per share (Rs) Rs 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total assets 1,216.0 1,216.0 982.4 811.2 804.6 822.9 977.9 972.6 961.6
Total equity 985.5 985.5 828.0 631.9 603.7 633.9 895.9 904.3 922.6
Total debt 33.4 33.4 27.4 31.4 37.9 34.7 38.1 25.5 19.4
Net cash from operating activities 9.0 17.3 (9.2) 6.8 (5.8) 250.4 (238.7) (13.0) (0.4)
Capital expenditure (50.0) (11.8) (23.3) (14.7) (0.2) (223.9) (13.3) (0.6) —
Free cash flow (operating cash flow − capex) (41.0) 5.4 (32.5) (7.9) (6.0) 26.4 (252.0) (13.6) —

Figures in Pakistani rupees as reported by the company; costs and cash outflows in brackets. Free cash flow and book value per share are calculated by Smart Money; TTM = the latest four quarters. Updated 17 Oct 2026.

LIVEN charts

Revenue and profit Revenue Profit attributable
Revenue and profit Rs 127 mn -Rs 584 mn Revenue FY17: Rs 0 Profit attributable FY17: -Rs 37.6 mn FY17 Revenue FY18: Rs 0 Profit attributable FY18: -Rs 56.5 mn FY18 Revenue FY19: Rs 0 Profit attributable FY19: -Rs 15.2 mn FY19 Revenue FY20: Rs 0 Profit attributable FY20: -Rs 16.9 mn FY20 Revenue FY21: Rs 0 Profit attributable FY21: -Rs 14.6 mn FY21 Revenue FY22: Rs 0 Profit attributable FY22: -Rs 14.3 mn FY22 Revenue FY23: Rs 0 Profit attributable FY23: -Rs 12.3 mn FY23 Revenue FY24: Rs 0 Profit attributable FY24: -Rs 11.2 mn FY24 Revenue FY25: Rs 127.3 mn Profit attributable FY25: -Rs 584.5 mn FY25 Revenue FY26: Rs 105.8 mn Profit attributable FY26: -Rs 31.1 mn FY26
Margins Gross margin Operating margin Net margin
Margins 64% -198% -459% Gross margin FY25: 14.1% Gross margin FY26: 25.2% Operating margin FY25: -384.9% Operating margin FY26: -59.0% Net margin FY25: -459.2% Net margin FY26: -29.4% FY17 FY18 FY19 FY20 FY21 FY22 FY23 FY24 FY25 FY26
Cash flow Operating cash flow Capex Free cash flow
Cash flow Rs 9 mn -Rs 35 mn Operating cash flow FY17: -Rs 5.1 mn FY17 Operating cash flow FY18: -Rs 4.8 mn FY18 Operating cash flow FY19: -Rs 1.8 mn FY19 Operating cash flow FY20: -Rs 1.9 mn FY20 Operating cash flow FY21: -Rs 6.8 mn FY21 Operating cash flow FY22: -Rs 2.3 mn FY22 Operating cash flow FY23: -Rs 2.3 mn FY23 Operating cash flow FY24: -Rs 878,217 FY24 Operating cash flow FY25: -Rs 1.7 mn Capex FY25: -Rs 32.8 mn Free cash flow FY25: -Rs 34.6 mn FY25 Operating cash flow FY26: Rs 9.0 mn Capex FY26: -Rs 29.7 mn Free cash flow FY26: -Rs 20.7 mn FY26

Valuation

LIVEN valuation at today's price

Price to earnings (P/E)
—
EPS Rs -0.28 (FY2026)
Price to book (P/B)
4.50×
Book value Rs 8.72 (FY2026)
Dividend yield
0.0%
DPS Rs 0.00 (FY2026)
Earnings yield
-0.7%
EPS ÷ price

At the closing price of Rs 39.19 on 13 Nov 2026. P/E and P/B are not shown when earnings or book value are negative.

Sector peers

LIVEN vs Pharmaceuticals companies

Largest companies in the sector at today's prices
Company Market cap P/E P/B Yield ROE 3-yr growth
LIVEN Rs 4.4 bn — 4.50× 0.0% -3.8% —
GLAXO Rs 107.1 bn 10.3× 3.11× 5.1% 32.4% 16.3%
ABOT Rs 97.9 bn 11.4× 3.05× 4.0% 28.8% 15.2%
HALEON Rs 81.6 bn 12.4× 5.02× 4.3% 47.6% 16.2%
HINOON Rs 50.8 bn 12.8× 3.95× 5.2% 32.3% 20.5%
AGP Rs 43.8 bn 11.7× 2.92× 5.1% 25.9% 26.0%
HPL Rs 38.5 bn 10.3× 4.50× 6.0% 38.6% 18.6%
FEROZ Rs 15.8 bn 16.1× 1.19× 1.5% 7.6% 27.9%
CPHL Rs 14.5 bn 18.3× 1.34× 0.0% 7.3% 4.3%

All Pharmaceuticals companies, medians and leaders →

Analyses & signals 0

Win rate — · 0 closed signals · average return —

No analyses published for LIVEN yet.

LIVEN: frequently asked questions

What is LIVEN's EPS?

Liven Pharma Limited reported basic earnings per share of Rs -0.28 for FY2026 (Jul 2025 – Jun 2026).

Does LIVEN pay dividends?

Liven Pharma Limited did not declare a cash dividend for FY2026.

What was LIVEN's revenue and profit in FY2026?

Liven Pharma Limited reported revenue of Rs 105.8 mn and profit attributable to shareholders of -Rs 31.1 mn for FY2026 (Jul 2025 – Jun 2026).

What is LIVEN's book value per share?

Liven Pharma Limited's book value per share was Rs 8.72 at the end of FY2026. The shares trade at 4.50× book value.

How has LIVEN's share price performed?

LIVEN's share price is down 24.6% year to date (KSE-100: +2.2%), down 19.3% over one year (KSE-100: +10.7%) and up 73.0% over five years (KSE-100: +288.8%), as of 13 Nov 2026. These are price returns; dividends are not included.

Information only, not investment advice.